Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 3 2Phase 2 1Phase 1/2 1

Status

Active not recruiting 5Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 8OTHER 2

Study Type

Interventional 8

Sponsor

Cancer Type

Breast 8Gynecologic 2Head & Neck 1

Conditions

Breast Neoplasms 8Endometrial Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Breast Diseases 1

Interventions

Trastuzumab 242Paclitaxel 223Fulvestrant 196Capecitabine 182Docetaxel 164Letrozole 142pembrolizumab 115Carboplatin 100exemestane 98Gemcitabine 98Cyclophosphamide 92palbociclib 86Anastrozole 83pertuzumab 78Lapatinib 73Bevacizumab 71ribociclib 68130-nm albumin-bound paclitaxel 66abemaciclib 59eribulin 58Doxorubicin 55Vinorelbine 51Injections 47Ado-Trastuzumab Emtansine 47Tamoxifen 45Everolimus 44Albumin-Bound Paclitaxel 44atezolizumab 35trastuzumab deruxtecan 34Nivolumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
INDUSTRY × Imlunestrant × Breast × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT07287098 2026-05-22

preEMBER

Eli Lilly and Company

Phase 2 Not yet recruiting
600 enrolled
Breast

Breast Neoplasms

NCT05307705 2026-04-20

PIKASSO-01

Eli Lilly and Company

Phase 1 Active not recruiting
193 enrolled
Breast

Breast Neoplasms

NCT05509790 2026-04-13

A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer

Eli Lilly and Company

Phase 1 Active not recruiting
17 enrolled
Breast

Breast Neoplasms

NCT05514054 2026-04-02

EMBER-4

Eli Lilly and Company

Phase 3 Active not recruiting
8,000 enrolled
Breast

Breast Neoplasms

NCT04647487 2025-11-12

EMBER-2

Eli Lilly and Company

Phase 1 Completed
87 enrolled 13 charts
Breast

Breast Neoplasms

NCT04975308 2025-07-11

EMBER-3

Eli Lilly and Company

Phase 3 Active not recruiting
874 enrolled 29 charts 1 FDA
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04188548 2025-06-04

EMBER

Eli Lilly and Company

Phase 1 Active not recruiting
500 enrolled
BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡